Do NSAIDs prevent colorectal cancer?

Canadian Journal of Gastroenterology

Volumn 14, Issue 4, 2000, Pages 299-307

  Arber, Nadir ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Acetylsalicylic acid; Colorectal cancer; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SULINDAC; SULINDAC SULFONE;

APOPTOSIS; CANCER RISK; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CELL CYCLE; CLINICAL TRIAL; COHORT ANALYSIS; COLON POLYPOSIS; COLORECTAL CANCER; DRUG MECHANISM; EARLY DIAGNOSIS; ENZYME INHIBITION; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW;

EID: 0034062291     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/245964     Document Type: Review

References (112)

1. Vane JR, Flower RJ, Botting RM. History of aspirin and its mechanism of action. Stroke 1990:21(12 Suppl):IV12-23.
2. Vainio H, Morgan G. Aspirin for the second hundred years: new users for an old drug. Pharmacol Toxicol 1997;81:151-2.
3. Cole P, Sateren W. The evolving picture of cancer in America. J Natl Cancer Inst 1995;87:159-60.
4. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
5. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
6. Morson B. President's address. The polyp-cancer sequence in the large bowel. Proc R Soc Mes 1974;67:451-7.
7. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
8. Hamilton SR. The molecular genetics of colorectal neoplasia. Gastroenterology 1993;105:3-7.
9. Winawer SJ, Zauber AG, O'Brien MJ, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. N Engl J Med 1993;328:901-6.
10. Kelloff G. Chemoprevention of colorectal. In: Young G, Rozen P, Levin B, eds. Prevention and Early Detection of Colorectal Cancer. Philadelphia: WB Saunders, 1996:116-39.
11. Reddy BS, Naylini J, Tokumo K, Rigotty J, Zang E, Kelloff G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal anti-inflammatory drug with D,L-alpha-difluoromnthylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 1990;50:2562-8.
12. Craven PA, DeRuberits FR. Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis. Carcinogenesis 1992;13:541-6.
13. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethance-induced colon carcinogenesis in F344 rates. Carcinogenesis 1993;14:1493-7.
14. Reddy BS, Tokumo K, Kulkarni N, Aligia C, Kelloff G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 1992;13:1019-23.
15. Rao CV, Rivenson AJ, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995;55:1464-72.
16. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983;24:83-7.
17. Waddell WR, Ganser GF Cerise EJ, Loughry RW. Sulindac for polyposis of colon. Am J Surg 1989;157:175-9.
18. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991;115:952-4.
19. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-9.
20. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in fmilial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
21. Marnette LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:5575-89.
22. Vainio H, Morgan G, Kleihues P. An international evaluation of the cancer preventive potential of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 1997;6:749-53.
23. Thun MJ. NSAIDs use and decrease risk of gastrointestinal cancers. Gastroenterol Clin North Am 1996;25:333-47.
24. DuBois RN, Giardiello FM, Smalley WE. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am 1996;25:773-91.
25. Thun MJ. Aspirin and gastrointestinal cancer. Adv Exp Med Biol 1997:400A:395-402.
26. Waddell WR, Gerner RE. Indomethacin and ascorbate inhibit desmoid tumors. J Surg Oncol 1980;15:85-90.
27. Kudo T, Narisawa T, Abo S. Antitumor activity of indomethacin on methylazoxymethanol - induced large bowel tumors in rats. Gann 1980:71:260-4.
28. Takeo MT. Cyclooxygenase-2 inhibitors in tomorigenesis (Part II). Natl Cancer Inst 1998;90:1609-20.
29. Levy GN. Prostaglandin H synthases, nonsteroidal anti-inflamatory drugs, and colon cancer. FASEB J 1997;11:234-47.
30. Reddy BS, Maruyama H, Kelliff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987;47:5340-6.
31. Wargovich MJ, Chen CD, Harris C, Yang E, Velasco M. Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the colon. Int J Cancer 1995;60:515-9.
32. Beazer-Barclay Y, Levy DB, Moser AR, et al. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 1996;17:1757-60.
33. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322-5.
34. Oshima M, Oshima H, Kitagawa K. Loss of APC heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated APC gene. Proc Natl Acad Sci USA 1995;92:4482-6.
35. Giardiello FM. NSAIDs-induced polyp regression in familial adenomatous polyposis patients. Gastroenterol Clin North Am 1996;25:349-61.
36. Nuegent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on doudenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618-9.
37. Parker AL, Kadakia SC, Maccini DM, et al. Disappearance of duodenal polyps in Gardner's syndrome with sulindac therapy. Am J Gastroenterol 1993;88:93-4.
38. Spagnesi TM, Tonelli F, Dolara P, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994;106:362-6.
39. Luk GD. Prevention of gastrointestinal cancer - the potential role of NSAIDs in colorectal cancer. Schweiz Med Wochenschr 1996;126:801-12.
40. Marnette LJ. Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer. Prev Med 1995;24:103-6.
41. Gann PH, Manson JE, Glunn RJ, Hennekens CH. Low dose aspirin and incidence of colorectal tumors in randomized trial. J Natl Cancer Inst 1993;85:1220-4.
42. Stumer T, Glynn RJ, Lee IM, et al. Aspirin use and colorectal cancer: Post trial follow-up data from the Physicians Health Study. Ann Intern Med 1998;128:713-20.
43. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic disease: A cohort study of the elderly. BMJ 1989;299:247-50.
44. Paganini-Hill A. Aspirin and colorectal cancer: The Leisure World cohort revisited. Prev Med 1995;24:113-5.
45. Smalley W, Ray WA, Daugherty J, Griffin MR. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer. Arch Intern Med 1999;159:161-6.
46. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control result from the Melbourne Colorectal Cancer Study. Cancer Res 1988:48:4399-404.
47. Muscat JE, Wynder EL. Anti-inflammatory drugs and rheumatoid arthritis. J Natl Cancer Inst 1993;85:921-2.
48. Peleg II, Lubin MF, Cotsonis GA, Clarck WS, Wilcox CM. Long-term use of nonsteroidal anti-inflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci 1996;41:1319-26.
49. Reeves MJ, Newcomb PA, Trentham-Dietz A, Storer BE, Remington PL. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 1996;5:955-60.
50. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993;72:1171-7.
51. Rosenberg L, Palmer RJ, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991,83:355-8.
52. Muller AD, Sonnenberg A, Wasserman IH. Disease preceding colon cancer. A case-control study among veterans. Dig Dig Sci, 1994;39:2480-4.
53. Peleg II, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994;154:394-9.
54. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer 1994;74:1847-54.
55. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
56. Giovanucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
57. Rosenberg L, Louick C, Shapiro S. Nonsteroidal anti-inflammatory drug use and reduced risk of large bowel carcinoma. Cancer 1998;82:3326-33.
58. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-6.
59. Schreinemachers DM, Everson RB. Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
60. Cibere J, Sibley J, Haga M. Rheumatoid arthiritis and the risk of malignancy. Arthritis Rheum 1997;40:1580-6.
61. Kauppi M, Pukkala E, Isomaki H. Low incidence of colorectal cancer in patients with rheumatoid arthritis. Clin Exp Rheumatol 1996:14:551-3.
62. Girdley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with arthritis. J Natl Cancer Inst 1993;85:307-11.
63. Breuer-Katschinski B, Nemes K, Rump B, et al. The colorectal adenoma study group. Long-term use of nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas. Digestion 2000;61:129-134.
64. Martinez ME, McPherson RS, Levin B, Annegers JF. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol Biomarkers Prev 1995;4:703-7.
65. Sandler RS, Calanko JC, Murry SC, Helam JF, Woosley JT. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 1998;114:441-7.
66. Logan RF, Little J, Hawltin PG, Hardcastle JD. Effect of aspirin and nonsteroidal anti-inflammatory drugs on colorectal adenomas: case control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 1993;307:285-9.
67. Greenberg ER, Baron JA, Freeman DHJ, Mandel JS, Haile R. Reduced risk of large-bowel adenomas among aspirin users: The Polyp Prevention Study Group. J Natl Cancer Inst 1993;85:912-6.
68. Landenheim J, Garcia G, Titzer D, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995;108:1083-7.
69. Hixson LJ, Earnest DL, Fennerty MB, Sampliner RE. NSAID effect on sporadic colon polyps. Am J Gastoenterol 1993;88:1652-6.
70. Disario JA, Alberts ES, Tietze CC, et al. Sulindac induces regression and prevents progression of sporadic colorectal adenomas. Gastroenterology 1997:112:A555. (Abst)
71. DuBois RN. Nonsteroidal anti-inflammatory drugs use and sopradic colorectal adenomas. Gastroenterology 1995;108:1310-4.
72. Shiff SJ, Rigas B. Nonsteroidal anti-inflamatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology 1997;113:1992-8.
73. Bannett A, Del Tacca M. Prostaglandins and human colon carcinoma. Gut 1975;16:409.
74. Hixson LJ, Alberts DS, Krutzsch M, et al. Anti-proliferative effect on nonsteroidal anti-inflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers Prev 1994;3:433-8.
75. Alberts DS, Hixson LJ, Ahnen D, et al. Do NSAIDs exert their colon chemoprevention activities through the inhibition of mucosal prostaglandin synthesis. J Cell Biochem 1995;22:18-23.
76. Shiff SJ, Qiao L, Tsai L-L, Rigas B. Sulindac suldide, an aspirin like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995;96:491-503.
77. Chan TA. Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal anti-inflammatory drug mediated apoptosis. Proc Natl Acad Sci USA 1998;95:681-6.
78. Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 1997;100:1325-9.
79. Ahnen DJ. Colon cancer prevention by NSAIDs: What is the mechanism of action? Eur J Surg Suppl 1998;582:111-4.
80. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part I). Natl Cancer Inst 1998;90:1529-36.
81. Duggan DE, Hooke KF, Hwang SS. Kinetics of the tissue distributions of sulindac and metabolites: relevance to sites and rates of bioactivation. Drug Metab Dispos 1980;8:241-6.
82. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxidase synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-4.
83. Eberhart CE, Dubois RN. Eicosanoids and the gastrointestinal tract. Gastroenterology 1995;109:285-301.
84. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556-9.
85. Heath CW, Thun MJ, Greenberg ER, Levin B, Marnett LJ. Nonsteroidal anti-inflammatory drugs and human cancer. Cancer 1994;74:2885-8.
86. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal and adenocarcinomas. Gastroenterology 1994;107:1183-8.
87. Garay CA, Engstrom PF. Chemoprevention of colorectal cancer: dietary and pharmacologic approaches. Oncology (Huntingt) 1999;13:89-97.
88. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and-2 human colorectal cancer. Cancer Res 1995;55:3685-9.
89. Arber N, Han E.K-H, Sgambato A, et al. Transformation of rat enterocytes by a c-K-ras oncogene increases resistance to growth inhibition and apoptosis induced by sulindac sulfide. Gastroenterology 1997;113:1892-900.
90. Goldberg Y, Nassif II, Pittas A, et al. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 1996;12:893-901.
91. Shift SJ, Koutsos MI, Quiao L, Rigas B. Nonsteroidal anti-inflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 1996;222:179-188.
92. Piazza G, Rahm ALK, Pamukcu R, Ahnen DJ. Induction of apoptosis by sulindac metabolites involves a p53 and bcl-2 independent mechanism and does not require cell cycle arrest. Gastroenterology 1996;110:577A. (Abst)
93. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254-9.
94. Piazza GA, Kulchak Rabm AL, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995;55:3110-6.
95. Piazza GA, Rahm AK, Finn B, Stoumen AL, Pamukcu R, Ahnen DJ. Apoptosis fully accounts for the growth inhibitory properties of sulindac metabolites by a mechanism independent of cyclooxygenase inhibition, cell cycle arrest or p53 mediation. Cancer Res 1997;57:2452-9.
96. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in APC knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
97. Fukutake M, Nakatsugi S, Isoi T, et al. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymthane-induced colon carcinogenesis in mice. Carcinogenesis 1998;19:1939-42.
98. Hale AJ, Smith CA, Sutherland LC, et al. Apoptosis: molecular regulation of cell death. Eur J Biochem 1996;236:1-26.
99. Piazza GA, Fryer BJ, van Stolk RU, et al. Selective apoptosis of neoplastic cells accompanies polyp regression in familial adenomatous polyposis (FAP) patients treated with FGN-1 (sulindac sulfone): evidence for a cyclooxygenase independent mechanism. Gastroenterology 1997;112:A638.
100. Qiao L, Shiff SJ, Rigas B. Sulindac sulfide inhibits the proliferation of colon cancer cells: diminished expression of the proliferation markers PCNA and ki-67. Cancer Lett 1997;115:229-34.
101. Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995;109:994-8.
102. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal antiinflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52:237-45.
103. Hale AJ, Smith CA, Sutherland LC, et al. Apoptosis: molecular regulation of cell death. Eur J Biochem 1996;236:1-26.
104. DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD. GI delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 1996;56:733-7.
105. Tsioulias G, Godwin TA, Goldstein MF, et al. Loss of colonic HLA antigens in familial adenomatous polyposis. Cancer Res 1992;52:3449-52.
106. Tsioulias GJ, Triadafilopoulos G, Goldin E, et al. Expression of HLA class I antigens in sporadic adenomas and histologically normal mucosa of the colon. Cancer Res 1993;53:2374-8.
107. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556-9.
108. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1994;84:493-501.
109. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996;56:4566-71.
110. Singh J, Hamid R, Reddy BS. Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitation stage of colon carcinogenesis. Cancer Res 1997;57:3465-70.
111. van Stolk RU, DeYoung B, Church JM, et al. Clinco-pathologic correlation of rectal adenoma in patients with familial adenomatous polypsosis (FAP) treated with sulindac sulfone in a phase I\II trial. Gastroenterology 1997;112:A673. (Abst)
112. Piazza GA, Li H, Liu L, et al. Cyclic GMP (CG) phosphodiesterase (PDE) inhibition: A novel mechanism for the antineoplastic properties of exisulind. Gastroenterology 1999;116:A485. (Abst)